摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-sec-butyl-4-aminopiperidine | 1016820-77-1

中文名称
——
中文别名
——
英文名称
N-sec-butyl-4-aminopiperidine
英文别名
1-(Sec-butyl)piperidin-4-amine;1-butan-2-ylpiperidin-4-amine
N-sec-butyl-4-aminopiperidine化学式
CAS
1016820-77-1
化学式
C9H20N2
mdl
——
分子量
156.271
InChiKey
DBBKREWGWFNQHZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    5-甲基水杨酸N-sec-butyl-4-aminopiperidine1-羟基苯并三唑1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 N-(1-butan-2-ylpiperidin-4-yl)-2-hydroxy-5-methylbenzamide
    参考文献:
    名称:
    Salicylamide inhibitors of influenza virus fusion
    摘要:
    Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00335-8
  • 作为产物:
    描述:
    4-氨基哌啶丁酮 在 sodium cyanoborohydride 作用下, 生成 N-sec-butyl-4-aminopiperidine
    参考文献:
    名称:
    Salicylamide inhibitors of influenza virus fusion
    摘要:
    Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay. (C) 2000 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(00)00335-8
点击查看最新优质反应信息

文献信息

  • BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
    申请人:Agency for Science, Technology, and Research
    公开号:US20190315755A1
    公开(公告)日:2019-10-17
    The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
  • US9580425B2
    申请人:——
    公开号:US9580425B2
    公开(公告)日:2017-02-28
  • Salicylamide inhibitors of influenza virus fusion
    作者:Keith D. Combrink、H.Belgin Gulgeze、Kuo-Long Yu、Bradley C. Pearce、Ashok K. Trehan、Jianmei Wei、Milind Deshpande、Mark Krystal、Albert Torri、Guangxiang Luo、Christopher Cianci、Stephanie Danetz、Laurence Tiley、Nicholas A. Meanwell
    DOI:10.1016/s0960-894x(00)00335-8
    日期:2000.8
    Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system. This exercise resulted in the identification of a series of synthetically more accessible decahydroquinolines that retained the structural elements of BMY-27709 important for antiviral activity. The 2-methyl-cis-decahydroquinoline 6f was the most potent influenza inhibitor identified that demonstrated an EC50 of 90 ng/mL in a plaque reduction assay. (C) 2000 Elsevier Science Ltd. All rights reserved.
查看更多